• Home
  • About
  • Science
  • More
    • Home
    • About
    • Science
  • Home
  • About
  • Science

Unleashing the Immune System to Fight Cancer

Unleashing the Immune System to Fight CancerUnleashing the Immune System to Fight CancerUnleashing the Immune System to Fight Cancer

First-in-class checkpoint inhibitors that activate both Natural Killer cells and T cells.

Learn about our science

Today’s checkpoint inhibitors have transformed cancer care, but most patients still don’t respond. AGENTA Therapeutics is developing a new class of immunotherapies that target Siglec-7, a novel immune checkpoint, to help turn non-responders into responders. 


  • A Novel Checkpoint. Our antibodies block Siglec-7, an “off switch” tumors use to hide from Natural Killer (NK) cells.
  • Two Arms of Immunity. Our lead candidate, AGT-125, is designed to activate NK cells and T cells in a single molecule.
  • Proven Leadership. Founded by the team behind INOVIO Pharmaceuticals, with technology invented at The Wistar Institute.

Contact Us

Contact Us

To learn more about AGENTA, please contact Dr. J. Joseph Kim, Founder & CEO, at kim@agentatherapeutics.com.

AGENTA Therapeutics

Copyright © 2026 AGENTA Therapeutics - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept